The statements below are read from ACCRETION PHARMA LIMITED’s filed results, 3 filed quarters and 3 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: H2 FY25-26 · filed Jul 18, 2026 · audited
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | H2 FY25Mar 2025 | H1 FY26Sep 2025 | H2 FY26Mar 2026Latest | YoYlatest |
|---|---|---|---|---|
| Sales | 38.8 | 43.7 | 45.9 | +18.2% |
| 31.3 | 36.7 | 38.0 | +21.6% | |
| Operating profit | 7.54 | 7.07 | 7.88 | +4.5% |
| OPM % | 19.4% | 16.2% | 17.2% | -2.3 pp |
| Other income | 0.08 | 0.11 | 0.08 | +1.1% |
| Interest | 0.74 | 0.37 | 0.48 | -35.8% |
| Depreciation | 0.41 | 0.40 | 0.81 | +99.1% |
| Profit before tax | 6.47 | 6.41 | 6.67 | +3.1% |
| Tax % | 33.1% | 25.9% | 26.3% | -6.8 pp |
| Net profit | 4.33 | 4.75 | 4.92 | +13.5% |
| EPS (₹) | 5.30 | 4.61 | 4.42 | -16.6% |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
